Predictive factors for atrial fibrillation recurrence after radiofrequency ablation: a multifactorial approach

射频消融术后房颤复发的预测因素:多因素分析

阅读:1

Abstract

BACKGROUND: Radiofrequency ablation is a leading clinical method for restoring sinus rhythm in atrial fibrillation (AF) patients. However, the high recurrence rate and potential complications necessitate careful evaluation of its application. AIM: This study aims to identify predictive factors for post-ablation AF recurrence by integrating multiple preoperative clinical variables in AF patients. METHODS: A total of 270 patients with non-valvular AF undergoing first-time radiofrequency ablation were categorized into a recurrence group and a non-recurrence group. Univariate and multivariate logistic regression analyses were performed to identify independent risk factors for AF recurrence. Receiver operating characteristic (ROC) curves and the area under the curve (AUC) were used to evaluate the predictive value of related factors and a combined prediction model for AF recurrence. RESULTS: At one-year follow-up, AF recurred in 100 patients (37.04%). Logistic multifactor regression analysis identified left atrial diameter (LAD), N-terminal pro-brain natriuretic peptide (NT-proBNP), uric acid (UA), left atrial appendage blood flow velocity (LAAV), and early recurrence of AF (ERAF) as independent predictors of AF recurrence. The AUCs of LAD, NT-proBNP, UA and the combined prediction model for predicting AF recurrence after radiofrequency ablation were 0.674, 0.685, 0.652 and 0.785, respectively, with a statistically significant difference between single indicators and the combined model (P < 0.05). CONCLUSION: LAD, NT-proBNP, UA, LAAV, and ERAF are independent predictors of atrial fibrillation (AF) recurrence. The combined model of LAD, NT-proBNP, and UA shows better predictive ability than individual factors, offering a more reliable recurrence assessment. Our model, based on these three widely accessible markers, is simple, practical, and easily generalizable. However, the lack of external validation limits its applicability. Future studies should validate the model in independent cohorts to confirm its robustness and generalizability.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。